Edralbrutinib - Eternity Bioscience/TG Therapeutics
Alternative Names: EBI-1459; SHR-1459; TG-1701Latest Information Update: 17 Jul 2024
At a glance
- Originator Eternity Bioscience
- Developer Eternity Bioscience; Jiangsu Hengrui Medicine Co.; Reistone Biopharma; TG Therapeutics
- Class Amines; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenyl ethers; Pyridazines; Pyrroles; Pyrrolidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Membranous glomerulonephritis; Neuromyelitis optica; Non-Hodgkin's lymphoma
- Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
- Preclinical Mantle-cell lymphoma; Multiple sclerosis
Most Recent Events
- 27 Jun 2024 TG Therapeutics terminates the phase I trial in Non-Hodgkin's lymphoma as per strategic/business decision (Combination therapy, Second-line therapy or greater) in Australia and Poland (PO)
- 13 Feb 2023 Edralbrutinib is still in phase I trials for B cell lymphoma in China (PO)
- 13 Feb 2023 Jiangsu HengRui Medicine completes a phase I pharmacokinetic trial (In volunteers) for B-cell lymphoma in China (PO) (NCT05560360)